Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Bluejay Diagnostics, Inc. BJDX NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
29/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Bluejay Diagnostics, Inc. (BJDX) is a Medical - Devices company in the Healthcare sector, currently trading at $1.79. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: BJDX trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $7M (loss), growing at +8.6%/yr. Net profit margin is 0% (thin). Gross margin is 19.6% (+0 pp trend).

Balance sheet: total debt is $120,211 against $6M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.88 (strong liquidity). Debt-to-assets is 1.7%. Total assets: $7M.

Analyst outlook: 0 / 1 analysts rate BJDX as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 18/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

BJDX SharesGrow Score Overview

36/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 18/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BJDX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
40/100
BJDX: -100%/yr revenue is, +8.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BJDX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 4.88 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
18/100
BJDX: Gross margin is 19.6% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 18/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate BJDX as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.649-40.8
Volume4.15K
Avg Volume (30D)230.84K
Market Cap$811.84K
Beta (1Y)0.67
Share Statistics
EPS (TTM)-15.25
Shares Outstanding$449.04K
IPO Date2021-11-10
Employees7
CEOIndranil Dey
Financial Highlights & Ratios
EBITDA$-6.68M
Net Income$-6.85M
Operating Income$-6.95M
Total Cash$5.16M
Total Debt$120.21K
Net Debt$-5.04M
Total Assets$7.12M
Price / Earnings (P/E)-0.1
Analyst Forecast
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS0956336087

Price Chart

Track all markets on TradingView
BJDX
Bluejay Diagnostics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Devices
1.65 52WK RANGE 40.80

People Also View

IRIX
IRIX
IRIDEX Corporation
$1.03
+0.97%
 NXL
NXL
Nexalin Technology, Inc.
$0.41
-4.15%
 TLIS
TLIS
Talis Biomedical Corporation
$2.84
+0.00%
 HSCS
HSCS
Heart Test Laboratories, Inc.
$1.97
-0.76%
 INVO
INVO
INVO Bioscience, Inc.
$0.83
-2.00%
 BBLG
BBLG
Bone Biologics Corporation
$1.26
+2.44%
 NUWE
NUWE
Nuwellis, Inc.
$1.23
+2.50%
 TIVC
TIVC
Tivic Health Systems, Inc.
$0.93
+2.04%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message